n and novel disease-causing mutations accessible for routine clinical practice. After years of development and rigorous validation, Good Start Genetics has harnessed the power of next-generation sequencing and other best-in-class technologies to provide highly accurate, actionable, and affordable tests for all ACOG and ACMG recommended disorders. For these reasons, fertility specialists and their patients can have a high degree of confidence in their carrier screening results, and no longer have to compromise accuracy for price.
For more information, please visit www.goodstartgenetics.com
OrbiMed is a preeminent investment firm dedicated exclusively to the healthcare sector with over $5 billion in assets under management. OrbiMed invests across the entire spectrum of pharmaceutical, biotechnology and medical device companies on a worldwide basis. Investments are made through venture capital funds, hedge funds, and other investment vehicles. For more information, please visit www.orbimed.com.
About Safeguard Scientifics
Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital and operational support to entrepreneurial and innovative life sciences and technology companies. Specifically in life sciences, Safeguard targets companies in Molecular and Point-of-Care Diagnostics, Medical Devices, Regenerative Medicine, Specialty Pharmaceuticals and selected healthcare services, and technology companies in Internet / New Media, Financial Services IT, Healthcare IT and selected business services with capital requirements of up to $25 million. For more information, please visit www.safeguard.com.
About SV Life Sciences
SV Life Sciences is a venture capital
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Good Start Genetics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Startling results in synthetic chemistry presented in Nature Chemistry2
. JumpStart Invests $250,000 in Milo Biotechnology3
. Medisafe 1 Technologies to Start the $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share4
. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone5
. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management6
. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List7
. Garage Start-ups Now Possible in Life Sciences Industry8
. Angioslide Named One of Israels Top Ten Most Promising Startups of 20119
. False starts can sneak by in womens sprinting10
. Good Start Genetics™ Announces Validation Results for its Next-Generation DNA Sequencing Platform for Genetic Disorder Carrier Screening11
. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV